Reasonable therapy for bronchial asthma: single inhaler strategy
- Authors: Babak S.L.1, Gorbunova M.V1, Malyavin A.G1
-
Affiliations:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 26, No 5 (2019)
- Pages: 70-78
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/297610
- DOI: https://doi.org/10.18565/pharmateca.2019.5.70-78
- ID: 297610
Cite item
Open Access
Access granted
Abstract
Background. Therapy of patients with bronchial asthma (BA) depends on a variety of multidirectional factors, such as the phenotype of the disease, severity, the presence of concomitant diseases, the response to therapy. There are two most discussed main strategies: regular BA treatment with an established dose with stepwise correction (step up/down) or a single inhaler strategy with “quantum satis" dosing. The purpose of this publication is to present a new strategy and modern approaches for the reasonable treatment of BA with a single inhaler (fixed combination of budesonide/formoterol in the “turbuhaler" device) with the possibility of its implementation in actual clinical practice. Conclusion. In real clinical practice, therapy of asthma patient should not face serious difficulties of execution, if the practitioner has modern capabilities of combined pharmacotherapy and non-drug correction methods, and is able to successfully plan a therapeutic strategy. A modern rational therapeutic strategy for treating patients with asthma should recognize the reasonable dosing of fixed BUD/ FOR combinations in a single inhaler mode. The priority doctrine of treating patients with asthma should be “quantum satis" therapy, which allows achieving a long-lasting, positive effect.
Full Text
About the authors
Sergey L. Babak
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: sergbabak@mail.iu
MD, Professor, Department of Phthisiology and Pulmonology
M. V Gorbunova
A.I. Evdokimov Moscow State University of Medicine and DentistryDepartment of Phthisiology and Pulmonology
A. G Malyavin
A.I. Evdokimov Moscow State University of Medicine and DentistryDepartment of Phthisiology and Pulmonology
References
- Global Strategy for Asthma Management and Prevention. Revised 2018. https://ginasthma.org/ gina-reports.
- Бронхиальная астма. Национальные клинические рекомендации Российского респираторного общества и Российской ассоциации аллергологов и клинических иммунологов. М., 2018. 90 с. URL: http://spulmo.ru/ obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii.
- Ilmarinen P, Tuomisto L.E., Niemela O., et al. Cluster Analysis on Longitudinal Data of Patients with Adult-Onset Asthma. J Allergy Clin Immunol Pract. 2017;5(4):967-78.e3. Doi: 10.1016/j. jaip.2017.01.027
- Wenzel S.E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-25. doi: 10.1038/nm.2678.
- Chung K.F. Clinical management of severe therapy-resistant asthma. Expert Rev Respir Med. 2017;11(5):395-402. doi: 10.1080/17476348.2017.13 1 7597.
- Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011;6:87-93.
- Pinnock H., Parke H.L., Panagioti M., et al.; PRISMS and RECURSIVE groups. Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC. Med. 2017;15(1):64. doi: 10.1186/s12916-017-0823-7.
- Давыдов Ю.Н. Максимилиан Вебер и проблема интерпретации рациональности. Вопросы социологии. 1996;6:71-7.
- Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci. (Lond). 2017;131(13):1541-58. Doi: 10.1042/ CS20160487.
- Nair P., Martin J.G., Cockcroft D.C., et al. Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. J. Allergy Clin Immunol Pract. 2017;5(3):649-59.e2. Doi: 10.1016/j. jaip.2016.11.030.
- Jenkins C.R., Eriksson G., Bateman E.D., et al. Efficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment. BMC Pulm Med. 2017;17(1):65. doi: 10.1186/s12890-017-0401-y.
- Milenkovic J., Alexopoulos A.H., Kiparissides C. Flow and particle deposition in the Turbuhaler: a CFD simulation. Int J. Pharm. 2013;448(1):205-13. doi: 10.1016/j.ijpharm.2013.03.004.
- Korn S., Vogelmeier C., Buhl R. Budesonide/ formoterol maintenance and reliever therapy. A new treatment approach for adult patients with asthma. Med Klin. (Munich). 2008; 103(5):299-310. doi: 10.1007/s00063-008-1050-y.
- Milenkovic J., Alexopoulos A.H., Kiparissides C. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach. Int J. Pharm. 2014;461(1-2):129-36. doi: 10.1016/j.ijpharm.2013.11.047.
- O'Byrne PM., FitzGerald J.M., Bateman E.D., et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N. Engl J. Med. 2018;378(20):1865-76. Doi: 10.1056/ NEJMoa1715274.
- Bateman E.D., Reddel H.K., O'Byrne PM., et al. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N. Engl J. Med. 2018;378(20):1877-87. Doi: 10.1056/ NEJMoa1715275.
- Рекомендации экспертов российского респираторного общества. 2017. [Recommendations of experts of the Russian respiratory society.] URL: http://spulmo.ru/upload/mneniya_eksperiov_ RRO.pdf
- Global Initiative for Asthma. Pocket guide 2019, 08.05.2019 URL: httos://ginasthma.o_gU wp-contenУ/upluods/nQl9/04/GI/G-2019main-Pocket-Guide-wms.pdf
- Инструкция по медицинскому применению лекарственного препарата Симбикорт®Турбухалер® 80/4,5 мкг/доза, 160/4,5 мкг/доза (порошок для ингаляций дозированный) от 11.04.2019. Регистрационное удостоверение П NG13167/G1 от 28.G4.2G11 (переоформлено 96.19.9G18)
Supplementary files
